Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas (original) (raw)

Abstract

Purpose To assess the frequency of chromosomes 1p and 19q deletions in gliomas and to correlate 1p deletion with prognosis in patients with grade 2 and grade 3 gliomas independently of histologic subtype. Methods We retrospectively evaluated 208 patients with WHO grade 2 and 3 gliomas who had 1p/19q molecular studies performed between 2000 and 2004. DNA was extracted from tumor tissue and germline material and evaluated by PCR using microsatellite markers for each chromosome. Results There were 113 men and 95 women with a median age at diagnosis of 40. Thirty-eight patients had a low-grade astrocytoma (A2), 58 low-grade oligodendroglioma (O2), 31 low-grade oligoastrocytoma (OA2), 21 anaplastic astrocytoma (A3), 37 anaplastic oligodendroglioma (O3), and 23 had an anaplastic oligoastrocytoma (OA3). Chromosome 1p analysis was performed in all patients and showed deletions in 105 patients (76% of O2, 42% of OA2, 21% of A2, 89% of O3, 17% of AO3, and 14% of A3). Chromosome 19q studies were performed in 118 patients and showed deletions in 46 (56% of O2, 45% of OA2, 27% of A2, 76% of O3, 11% of OA3 and 0% of A3). On multivariate analyses, chromosome 1p was a prognostic factor for prolonged PFS (HR = 1.75, P = 0.03) and OS (HR = 3.59, P = 0.02) in grade 2 gliomas but not for grade 3 (HR = 0.81, P = 0.7 for PFS; HR = 1.31, P = 0.7 for OS). Conclusion Chromosome 1p deletion is a significant positive prognostic marker in diffuse, grade 2 gliomas regardless of histologic subtype.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Ransom DT, Ritland SR, Kimmel DW, Moertel CA, Dahl RJ, Scheithauer BW et al (1992) Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas. Genes Chromosomes Cancer 5:348–356
    Article PubMed CAS Google Scholar
  2. Bello MJ, Vaquero J, de Campos JM, Kusak ME, Sarasa JL, Saez-Castresana J et al (1994) Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors. Int J Cancer 57:172–175
    Article PubMed CAS Google Scholar
  3. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479
    Article PubMed CAS Google Scholar
  4. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European organisation for research and treatment of cancer phase III trial. J Clin Oncol 24:2715–2722
    Article PubMed CAS Google Scholar
  5. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup radiation therapy oncology group trial 9402. J Clin Oncol 24:2707–2714
    Article PubMed CAS Google Scholar
  6. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M et al (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852–9861
    Article PubMed CAS Google Scholar
  7. Griffin CA, Burger P, Morsberger L, Yonescu R, Swierczynski S, Weingart JD et al (2006) Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 65:988–994
    Article PubMed Google Scholar
  8. Mariani L, Deiana G, Vassella E, Fathi AR, Murtin C, Arnold M et al (2006) Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy. J Clin Oncol 24:4758–4763
    Article PubMed CAS Google Scholar
  9. Kujas M, Lejeune J, Benouaich-Amiel A, Criniere E, Laigle-Donadey F, Marie Y et al (2005) Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas. Ann Neurol 58:322–326
    Article PubMed CAS Google Scholar
  10. Giannini C, Scheithauer BW, Weaver AL, Burger PC, Kros JM, Mork S et al (2001) Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 60:248–262
    PubMed CAS Google Scholar
  11. Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M (2005) Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 11:1119–1128
    PubMed CAS Google Scholar
  12. Idbaih A, Marie Y, Pierron G, Brennetot C, Hoang-Xuan K, Kujas M et al (2005) Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol 58:483–487
    Article PubMed CAS Google Scholar
  13. Smith JS, Perry A, Borell TJ, Lee HK, O’Fallon J, Hosek SM et al (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636–645
    PubMed CAS Google Scholar
  14. Walker C, du Plessis DG, Joyce KA, Fildes D, Gee A, Haylock B et al (2005) Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Ann Neurol 57:855–865
    Article PubMed CAS Google Scholar
  15. Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M et al (2004) Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol (Berl) 108:49–56
    Article Google Scholar
  16. Scheie D, Andresen PA, Cvancarova M, Bo AS, Helseth E, Skullerud K et al (2006) Fluorescence in situ hybridization (FISH) on touch preparations: a reliable method for detecting loss of heterozygosity at 1p and 19q in oligodendroglial tumors. Am J Surg Pathol 30:828–837
    Article PubMed Google Scholar
  17. Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G et al (1999) Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18:4144–4452
    Article PubMed CAS Google Scholar

Download references

Acknowledgements

We thank Drs. Lisa M. DeAngelis and Marc Ladanyi for their advice and critical reading.

Author information

Author notes

  1. Linda Nicolardi
    Present address: Department of Medical Oncology, Istituto Oncologico Veneto-IRCCS Padova, Padova, Italy
  2. Alexis Demopoulos
    Present address: Department of Neurology, North Shore University Hospital, Manhasset, NY, USA

Authors and Affiliations

  1. Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY, 10021, USA
    Fabio M. Iwamoto, Linda Nicolardi, Alexis Demopoulos & Adília Hormigo
  2. Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    Violetta Barbashina, Paulo Salazar & Marc Rosenblum

Authors

  1. Fabio M. Iwamoto
    You can also search for this author inPubMed Google Scholar
  2. Linda Nicolardi
    You can also search for this author inPubMed Google Scholar
  3. Alexis Demopoulos
    You can also search for this author inPubMed Google Scholar
  4. Violetta Barbashina
    You can also search for this author inPubMed Google Scholar
  5. Paulo Salazar
    You can also search for this author inPubMed Google Scholar
  6. Marc Rosenblum
    You can also search for this author inPubMed Google Scholar
  7. Adília Hormigo
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toAdília Hormigo.

Rights and permissions

About this article

Cite this article

Iwamoto, F.M., Nicolardi, L., Demopoulos, A. et al. Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas.J Neurooncol 88, 293–298 (2008). https://doi.org/10.1007/s11060-008-9563-z

Download citation

Keywords